RxDoctor Payments Data

Michael Tseng, MD

Ophthalmology · Chicago, ILNPI 1124550793

Payments from drug & device makers

$1,271in general payments, 2019–2025

Across 40 payments — averaging $31.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$239
  • Tarsus Pharmaceuticals, Inc.$211
  • Bausch & Lomb Americas Inc.$207
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$123
  • Thea Pharma Inc.$101
  • Inspire Medical Systems, Inc.$96
  • plus $293 from 7 others

What the payments were for

  • Food & beverage$1,271100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,271 in reported general payments places this provider in the 45th percentile of 773 ophthalmology providers in Illinois.

See all ophthalmology providers in Illinois

Medicare billing

Part B allowed, 2024
$331,473
Medicare patients
605
Services billed
2,265

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast40$41,243
RestasisCyclosporine34$38,766
Prednisolone Acetate232$12,328
Loteprednol Etabonate39$6,391
Fluorometholone53$5,383
SimbrinzaBrinzolamide/Brimonidine Tart27$5,336
LumiganBimatoprost13$4,703
ValacyclovirValacyclovir Hcl69$3,979
Ketorolac Tromethamine121$2,998
MoxifloxacinMoxifloxacin Hcl99$1,879
Difluprednate17$1,565
Ofloxacin87$1,539
Brimonidine Tartrate25$1,118
Dorzolamide-TimololDorzolamide/Timolol/Pf12$1,045
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha86$833

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$73$43,46947 claims
Bausch & Lomb Americas Inc.Xiidra$207$41,24340 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$123$6,39139 claims
AlconSimbrinza$54$5,33627 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 773 ophthalmology providers in Illinois.

Other ophthalmology in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →